On November 18, 2021 Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, reported that leading independent proxy advisory firm, Glass Lewis & Co. (Glass Lewis), joins Institutional Shareholder Services (ISS) in recommending that Advaxis stockholders vote "FOR" the stockholder proposals relating to the Company’s proposed merger with Biosight (Press release, Advaxis, NOV 18, 2021, View Source [SID1234595769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In its report dated November 11, 2021, Glass Lewis stated1:

We believe the strategic rationale for the proposed transaction is generally reasonable from the perspective of Advaxis shareholders.

We find that the analyses presented by the advisor are reasonable and contain adequate disclosure. In particular, we note from the advisor’s Comparable Initial Public Offerings Analysis that the implied value of the proposed consideration for Biosight ($218 million) falls within the fair value range derived by the advisor using pre-money equity values observed in seven IPOs involving Phase 2 companies without completing a crossover financing ($187 million to $406 million) and well below the range derived using equity values observed in 12 IPOs involving Phase 2 companies with a focus on oncology ($648 million to $819 million).

Overall, we see no cause for significant shareholder concern with the strategic rationale or financial aspects of the proposed transaction, which would allow Advaxis shareholders to benefit from the development pipeline and stronger financial position of the combined company.

Based on the forgoing factors and the support of the board, we believe the proposed transaction is in the best interests of shareholders.
Commenting on the reports, Kenneth A. Berlin, President, Chief Executive Officer and Interim Chief Financial Officer of Advaxis, said, "We are pleased that both Glass Lewis and ISS support our proposed combination with Biosight and recommend that Advaxis shareholders vote "FOR" the stockholder proposals relating to the merger. Our Board, which unanimously approved this transaction, is confident that merging with Biosight will create a well capitalized and better-positioned Company to advance a broader portfolio of drug candidates aimed at addressing both liquid and solid tumors. We strongly urge all Advaxis stockholders to follow the recommendations of ISS and Glass Lewis and vote "FOR" the shareholder proposals relating to the proposed combination with Biosight."

The Special Meeting, initially held on November 16, 2021, has been adjourned to December 7, 2021 at 10:00 AM Eastern Time unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the merger and related matters. Advaxis stockholders will be able to attend and participate in the Advaxis special meeting online by visiting www.virtualshareholdermeeting.com/ADXS2021SM where they will be able to listen to the meeting live, submit questions and vote.

On November 18, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), the German-American cancer molecular diagnostics company, reported that the Supervisory Board appointed Dr. Andrew Lukowiak as President and Chief Scientific Officer with effect from December 1, 2021 (Press release, Epigenomics, NOV 18, 2021, View Source [SID1234595767]). Dr. Lukowiak, who has held senior management positions in the U.S. molecular diagnostics industry, will become a member of the Executive Board of Epigenomics and oversee Research and Development and Operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lukowiak (49) has over 20 years of management experience in the molecular diagnostics and life sciences industries. Prior to joining Epigenomics, Andrew served as CEO and Board Member for Millennium Health, a leading specialty toxicology laboratory. Dr. Lukowiak was also Chief Operating Officer of AltheaDx Inc., where he led the development, validation and launch of multiple Real-Time PCR tests for a broad array of disease states. Additionally, he was a senior R&D executive at GenMark Diagnostics and Hologic, where he was responsible for both PMA and 510(k) cleared products including the support and automation of an HPV test for cervical cancer. Dr. Lukowiak earned his doctorate in Genetics from the University of Georgia and his Bachelor of Science in Biology from Pennsylvania State University.

Heino von Prondzynski, Chairman of the Supervisory Board, stated: "The Supervisory Board is excited to add the significant executive management, clinical and technical expertise that Andrew brings to the Executive Board of Epigenomics AG. Dr. Lukowiak has continually demonstrated the ability to deliver innovative tests through the FDA and the reimbursement process that have then led to commercial success. His breadth and depth of experience is ideally suited for Epigenomics to successfully execute the strategic plan for Epi proColon "Next-Gen"."

"I am excited to join the Epigenomics team and execute the plan for Epi proColon Next-Gen"," said Dr. Lukowiak. "Epigenomics’ "Next-Gen" blood-based cancer test has the potential to significantly improve colon cancer screening rates and save lives. The company’s leadership and innovation in liquid biopsy is an ideal platform to deliver an easy-to-use Real-time PCR based solution for hospital-based laboratories."

On November 18, 2021 Scandion Oncology reported its third quarter report for 2021 (Press release, Scandion Oncology, NOV 18, 2021, View Source,c3455924 [SID1234595765]). The following is taken from the report.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bo Rode Hansen, President and CEO comments

"During the third quarter, Scandion Oncology has continued the transformation towards the Cancer Drug Resistance company according to the company’s strategy. We completed the first Capital Markets Day where we conveyed the strategy for the registrational path to market of our clinical programs."

Highlights during Q3 2021

On August 25, Scandion Oncology announced that the US Patent and Trademark Office (USPTO) will grant the company’s patent US11,103,481 directed to the use of SCO-101. The granted patent covers combi­nation therapy with Scandion Oncology’s first-in-class lead candidate SCO-101. The patent claims the use of SCO-101 in combination with different anti-cancer agents across many cancer indications.
On August 27, Scandion Oncology announced that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study.
On September 2, Scandion Oncology and Alligator Bioscience announced the conclusion of their collaboration with a very positive outcome.
On September 6, Scandion Oncology announced that the company has obtained approval from the Danish Medicines Agency and the Ethics Committee of the amendment of part 2 of the CORIST Phase II study. This means that the company can commence the inclusion of patients. To increase the recruitment rate, Scandion Oncology is expanding the number of sites in Denmark from 2 to 5 and plans to further add additio­nal sites in the EU.
On September 7, Scandion Oncology announced that the company has strengthened its Clinical Advisory Board with three international highly experienced Key Opinion Leaders in oncology.
On September 8, Scandion Oncology announced it will provide novel information on its lead candidate drug SCO-101 and a focused clinical strategy with a clear path to registration at its Capital Markets Day. The company will also communicate about its pipeline, future business opportunities and give an update from part 1 of the CORIST Phase II study.
Highlights after the end of the period

November 8, Scandion Oncology announ­ced that the timeline for read-out of the dose-finding clinical Phase Ib study PANTAX will be extended, and read-out is now expected in Q2-Q3 2022.
The third quarter report 2021 is available on the Company’s website: www.scandiononcology.com.

Audiocast today, November 18 at 10:00 am CET

Today at 10:00 Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.

At the end of the presentation there will be a Q&A session.
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on November 18, 2021, at 8:30 CET

On November 18, 2021 Oasmia reported that Interim report for the period January 1, 2021 – September 30, 2021
(Press release, Oasmia, NOV 18, 2021, View Source [SID1234595764])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIGNIFICANT EVENTS DURING THE THIRD QUARTER
In August, Oasmia strengthened its internal capabilities with the appointments of Kia Bengtsson as Head of Clinical Development and Johanna Röstin as Head of Regulatory Affairs with effect from October 1, 2021.
In September, Oasmia signed a license agreement with the Swiss-based FarmaMondo Group for the commercialization of Paclical (Apealea) in Russia and the Commonwealth of Independent States.
SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD
In October an Extraordinary General Meeting decided on adoption of a long-term incentive program based on employee stock options for senior executives in the company
In October Oasmia announced a global settlement of all disputes with MGC Capital, former Board Members of Oasmia and members of former management. The settlement will result in a negative cashflow effect of MSEK 24.5 but with a positive earnings effect of MSEK 32.5.
THIRD QUARTER: JULY 1, 2021 – SEPTEMBER 30, 2021
Consolidated net sales amounted to TSEK 11,920 (154)
Operating profit/loss var TSEK -29,572 (-35,194)
Net profit/loss after tax amounted to TSEK -30,987 (-36,784)
Earnings per share amounted to SEK -0.07 (-0.08)
THE PERIOD: JANUARY 1, 2021 – SEPTEMBER 30, 2021
Consolidated net sales amounted to TSEK 16,553 (201,628)
Operating profit/loss var TSEK -126,579 (15,117)
Net profit/loss after tax amounted to TSEK -129,873 (7,832)
Earnings per share amounted to SEK -0.29 (0.02)
CEO REVIEW
Transforming a business requires sustained effort and focus. Since I joined Oasmia in March 2020 we have set out a clear path to future growth as a sustainable global oncology business.

We’ve done this by:

rightsizing the Company and terminating commercial drug production
putting our finances in order by eliminating unnecessary operating expenditure
building our in-house capabilities to make us an attractive partner for innovative assets and companies
reducing business risks, such as resolving inherited legal issues, eliminating these potential liabilities
Creating these solid foundations means we are now well placed to deliver on our string of pearls strategy, putting in place a diversified portfolio of innovative cancer therapies through in-licensing and M&A. Our ambition is to build a pipeline focused on hard-to-treat and late-stage cancers using different approaches and mechanisms of action which offer us multiple shots on goal, de-risking our portfolio significantly and therefore increasing our chances of success. During the third quarter we made steady progress towards achieving this vision.

Resolving outstanding legal disputes
Post period end, we announced the global settlement of all outstanding legal disputes with MGC Capital, former Board Members of Oasmia and members of former management. The settlement will result in a negative cashflow of MSEK 24.5 but will result in a positive earnings effect of MSEK 32.5. Reported debt in relation to the MGC litigation of MSEK 80, as well as a receivable of MSEK 40, is settled as a result of the agreement, strengthening our financial position and eliminating borrowings on the balance sheet. This is excellent news and enables us to look forward rather than back.

Progressing our in-licensed and wholly-owned development-stage oncology assets
Cantrixil is the first product of our string of pearls strategy, in-licensed from Kazia Therapeutics in March. It targets a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells thought to be responsible for disease relapse. Patients with chemotherapy-resistant ovarian cancer have a very poor prognosis, and Cantrixil could offer a much-needed new therapeutic option. Positive Phase 1 results were presented at AACR (Free AACR Whitepaper) earlier this year and Phase 2 study preparations in advanced ovarian cancer are well underway. In September, our Scientific Advisory Board, composed of key opinion leaders in oncology, met in Stockholm for the first time. The Board is offering invaluable guidance on the design of the Cantrixil Phase 2 trial and the longer-term clinical and regulatory path. Securing drug product for the Phase 2 trial through manufacturing agreements with multiple parties is a complex process and initiation of the trial will be later than originally envisaged. We will communicate further on the proposed timetable for the Phase 2 study when we have clarity on the supply situation.

A Phase 1b trial of our second clinical-stage program, docetaxel micellar, in development for advanced prostate cancer, continued to recruit patients in Switzerland under the leadership of the Swiss Group for Clinical Cancer Research (SAKK). SAKK has made excellent progress, with three centers open and enrolment is still expected to be completed by the end of 2022.

Exploring the full potential of our technologies
We recently provided an update on our collaboration with the Karolinska Institutet in Sweden to explore the full potential of our XR-17 drug solubilization technology platform. Work on our line extension for XR-17, which we have named XR-18, is progressing well and is intended to offer expanded utility. We are also preparing to evaluate formulations of XR-17/18 with our licensed product candidate, Cantrixil.

Our recent research into XR-19, our dual encapsulation technology designed to encapsulate two active pharmaceutical ingredients (APIs) in one micelle, has yielded encouraging proof-of-concept data. However, we have assessed the commercial utility of this approach to be limited and have therefore decided not to develop new product candidates with this technology, focusing our resources on other development opportunities.

Organizational update
Having the right scientific, regulatory, development and commercial skills to make Oasmia an attractive business partner for oncology drugs and companies around the world is critical to our success. Over the past 18 months, we’ve built a first-class team in all these areas, and in August I was pleased to announce the appointments of Kia Bengtsson as Head of Clinical Development and Johanna Röstin as Head of Regulatory Affairs. Kia and Johanna significantly strengthen Oasmia’s internal drug development expertise, supporting our ability to move products through to commercialization and to evaluate new opportunities. Peter Selin has decided to step down as Chief Business Officer and the search for a replacement has been initiated. Peter will remain in his current role during his notice period.

Maximizing the potential from out-licensed products
Maximizing the potential of our partnered ovarian cancer therapy Apealea has been another important focus. In September, we signed a license agreement with the Swiss-based FarmaMondo Group for the commercialization of Apealea in Russia and the Commonwealth of Independent States, where it is known under the brand name Paclical. This agreement marks the completion of the out-licensing of Apealea globally and we anticipate the first royalties from partnerships during 2022.

Elevar has informed Oasmia that it is reviewing the clinical and regulatory pathway for Apealea in the US in order to maximize the product’s commercial potential. This may impact the clinical development timelines for Apealea in the US and Oasmia will update investors when firm information has been provided by Elevar.

Building the business through in-licensing and M&A
As well as driving our existing portfolio in Q3, we’ve made further progress in making Oasmia a more attractive partner for innovative therapies and companies, positioning ourselves to add value in the sweet spot of early-to-mid-stage product development, demonstrated by the in-licensing of Cantrixil.

I’m pleased to report that our continuing transformation and new capabilities has attracted interest from a number of parties and that we are currently evaluating several promising opportunities. I look forward to updating you on progress in due course.

I’d like to thank you all for your continued support at this exciting time for the business as we look ahead to completing our transition to become a global oncology business.

On November 18, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services (Press release, LabCorp, NOV 18, 2021, View Source [SID1234595763]). Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Adding Toxikon underscores our commitment to nonclinical development and advances our capabilities for both drug development and medical device testing," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. "This acquisition extends Labcorp’s portfolio of full-service drug development and medical device solutions from discovery to market approval."

Toxikon’s strategic location allows Labcorp to further engage with large pharmaceutical companies and biotech firms in the region on nonclinical work, as well as facilitating entry into medical device investigational device exemption (IDE) submissions. As such, Toxikon will also complement Labcorp’s existing nonclinical medical device efficacy and safety testing and the associated clinical work performed by Labcorp’s medical device and diagnostics unit.

Headquartered in Bedford, Mass., and with annual revenues of around $40 million, Toxikon maintains specialized, state-of-the-art facilities and a robust roster of pharmaceutical, biotech and medical device clients. Its highly trained staff provides an extensive portfolio of in vivo and in vitro testing and related consulting services to support life sciences companies. The facility in Bedford also has capacity for growth and provides Labcorp Drug Development with an opportunity to expand its traditional toxicology business.

"As a part of the Labcorp family, we will have an opportunity to broaden our impact through access to extensive resources, knowledge and support," said Dr. Laxman S. Desai, Toxikon’s founder, president and CEO. "Together, we can provide better outcomes for our clients and, ultimately, the health care providers and patients who depend on our continued success and innovation."

The transaction is expected to close during the fourth quarter of 2021, subject to customary closing conditions and regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Specific terms of the transaction were not disclosed.